We tested a population of over 60 patients with chronic myelogenous leukemia (CML) for changes in the structure and expression of the p53 gene, which is located on chromosome 17. Six of 27 (22%) blast crisis samples and 3 of 5 (60%) accelerated phase samples had rearrangements of chromosome 17, whereas only 3 of 42 (7%) chronic phase patients had cytogenetic changes in chromosome 17. There was no loss of heterozygosity during the transition t o blastic crisis among seven individuals who were informative for polymorphic probes for regions in or around the p53gene on 17p. One patient in the chronic phase and one patient in the blastic phase of the 61 CML patients studied exhibited rearrangements of the p53 gene that were detectable by Southern analysis. One p53 allele was HILADELPHIA chromosome-positive chronic myelog-
We tested a population of over 60 patients with chronic myelogenous leukemia (CML) for changes in the structure and expression of the p53 gene, which is located on chromosome 17. Six of 27 (22%) blast crisis samples and 3 of 5 (60%) accelerated phase samples had rearrangements of chromosome 17, whereas only 3 of 42 (7%) chronic phase patients had cytogenetic changes in chromosome 17. There was no loss of heterozygosity during the transition t o blastic crisis among seven individuals who were informative for polymorphic probes for regions in or around the p53gene on 17p. One patient in the chronic phase and one patient in the blastic phase of the 61 CML patients studied exhibited rearrangements of the p53 gene that were detectable by Southern analysis. One p53 allele was HILADELPHIA chromosome-positive chronic myelog-P enous leukemia (CML) is a disease in which the c-ubl oncogene on chromosome 9 is translocated to the breakpoint cluster region (bcr) gene of chromosome 22. ' The protein product of the bcr/ubl fusion gene formed by this translocation is a tyrosine-specific protein kinase with altered substrate specificity and specific activity.* Formation of the Philadelphia chromosome is either the first or second change in the evolution of the chronic phase in CML. 3 Despite the detail with which the Philadelphia chromosome translocation has been characterized at the molecular level, little is known about the subsequent genetic changes that are acquired during the evolution to blast crisis.
Because the cells of 10% to 20% of C M L blast crisis patients have been reported to have cytogenetic abnormalities in chromosome 17, interest has recently focused on the p53 gene, which appears to code for a gene located on the short arm of chromosome 17." 5 The protein product of the p53 gene that is elevated in ALL, lymphoma, and AML6-9 has been found to bind to the large T-antigen of SV40 and heat shock proteins."-" The p53 gene has been reported to complement the rus oncogene in the transformation of embryo fibroblasts.'* Altered expression has also been re-rearranged in the chronic phase patient and both p53 alleles were rearranged in the blastic phase patient. The p53 messenger RNA (mRNA) was of normal size (2.8 kb) in chronic phase and blast crisis, and the expression of the p53 gene was at least as high or higher in blast crisis as in the chronic phase of CML. The high incidence of abnormalities of chromosome 17 in blast-crisis CML found in our studies and the discovery of rearrangements of the p53 gene in two CML patients studied suggest that further study with probes for the p53 gene and anonymous polymorphic sites in chromosome 17 should be conducted in CML. 0 1990 b y The American Society of Hematology.
ported in CML for the c-myc protooncogene that exhibits some similarities with the p53 gene."-'3 Elevated levels of expression of the c-myc and p53 genes a t the messenger R N A (mRNA) level have been associated with increased proliferation of hematopoietic cells, and induction of differentiation has been associated with down-regulation of ~5 3 . '~-'~ Although p53 mRNA has been detected in lymphoid and myeloid leukemia cell lines as well as in C M L blasts from patients, the expression of the p53 protein has been variable in myeloid leukemia cell^.^'^ We analyzed the structure and expression of the p53 gene in 61 patients with CML. In 13 of these, we were able to study cells during the evolution from chronic phase to blast crisis. Only 2 of 61 CML patients analyzed in this series had rearrangements of the p53 gene detectable by Southern blot analysis. There was no loss of heterozygosity in seven informative individuals tested at polymorphic loci in and around thep53 gene during the transition from chronic phase to blastic phase in CML. Northern blot analysis showed that the p53 mRNA was of normal size and that the levels of both p53 and c-myc mRNA in the blast crisis cells of five CML patients were as high or higher than those found in chronic phase cells of two patients tested.
MATERIALS AND METHODS
After Ficoll-Hypaque density gradient cell separation, DNA was extracted from the peripheral blood nucleated cells and marrow cells of patients with CML, and from the cells of patients with accelerated phase and blastic crisis. We digested these samples with the following restriction endonucleases: EcoRI, HindIII, BglII, PvuII, and BclI. The DNA was then subjected to electrophoresis on a 0.8% agarose gel, transferred to a nitrocellulose filter and hybridized with a '*P end-labeled 1.6-kb htuII fragment of the p53 complimentary DNA (cDNA) (Fig 1) . We chose the 5' end of the p53 cDNA because the region 3' to the 1.6-kb PvuII fragment of thep53 cDNA contains repetitive sequences. Molecular weights (mol wts) of restriction fragments were determined through use of HindIIIdigested X DNA and HaeIII-digested PhiX174 DNA. Analysis of total RNA on Northern blots was also conducted with the 1.6-kb PVuII-PvuII fragment of a p53 cDNA probe, which was a gift from L. Smith (University of Nebraska Medical School, Omaha). 16 This cDNA probe contained sequences homologous to those in exons 5 to Table 3 .
11. The c-myc probe was obtained from ONCOR (Gaithersburg, MD 
RESULTS
Studies of chromosome 17. Sixty-one patients with Philadelphia chromosome-positive CML were studied by Southern analysis. Because we collected samples during both the chronic and blastic phases for 13 patients, the total number of chronic phase and blast crisis samples were 42 and 27, respectively. Three of 42 (7%) chronic phase samples had abnormalities of chromosome 17, whereas 6 of 27 (22%) blast crisis samples and 3 of 5 (60%) accelerated-phase samples studied had abnormalities of chromosome 17, as shown in Table 1 .
As shown in Fig 1 , a polymorphic BgZII site is located between exons 1 and 2 of the p53 gene. This BglII polymorphism has been previously shown to lead to 9.5-and 11.0-kb BglII fragments." As shown in Fig 2, when Southern blots that contained BglIIdigested DNA were hybridized with a 1.6-kb PvuII exonic cDNA p53 probe, 55 of 61 (88%) CML patients contained an 11.0-kb and a 2.8-kb BglII fragment. Eleven percent (seven patients) of the CML patients were heterozygous for an 11 .O-and a 9.5-kb BgZII fragment, and were homozygous for the 2.8-kb fragment. DNA of one patient (1.5%) had a 2.8-kb BglII fragment and was homozygous for the 9.5-kb Studies with polymorphic probes. fragment. These patients are listed in Table 2 (patients no. 10, 15, 19,22, 25, 32, and 46) . This variation in the large-mol-wt BgZII p53 fragment was shown to be due to a restriction site polymorphism, according to two criteria: digestion of the same DNA with three other restriction endonucleases showed no variation in restriction fragment size (Table l) , and digestion of fibroblasts and the leukemia cells from the same patient showed the same polymorphic BglII p53 fragments (Fig 2) .
Samples from 3 of 13 patients in chronic phase and blast crisis were heterozygous for the BglII polymorphism. None of these patients lost the BglII polymorphism during the transition from chronic phase to blast crisis. We also studied DNA from four chronic-and blastic-phase patients, who were informative for an anonymous polymorphic probe (pYNH37.3)," from the short arm of chromosome 17 and found no loss of heterozygosity during the transition from chronic phase to blast crisis. The CML patients used for this analysis are not included in Table 3 .
As shown in Table 2 , the DNA of only two of the patients contained changes in the lengths of the p53 gene fragments generated by three different restriction endonucleases used (patients 7 and 24). Neither of these patients had rearrangements detectable in chromosome 17 a t the cytogenetic level. We chose HindIII for our analysis because this enzyme generates a small fragment a t the 5' end and a large fragment a t the 3' end of the p53 gene. We chose BglII because it generates a small fragment at the 3' end and a large fragment a t the 5' end, thereby permitting us to test for rearrangements located both at the 5' and 3' ends of thep53 gene (Fig 1) . A Southern blot, which shows the 2.5-and 7.0-kb HindIII fragments from patients in whom no rearrangement of the@ gene had occurred, is presented in lanes 1 through 6 of Fig 3B .
In lane 7, Fig 3A, in which the Hind111 digest of the chronic phase DNA of patient 7 is presented, an abnormal 3.7-kb fragment is seen in addition to the normal-sized 2.5-kb and 7.0-kb HindIII fragments. The HindIII digest of the chronic phase sample of patient 7 in lane 8, Fig We also digested DNA from patient 7 in blast crisis (lane 6, Fig 3A) . Data in lanes 6 and 7, Fig 3A, show that the p53 rearrangement discussed above was present in the first chronic phase sample analyzed (lane 7, Fig 3A) but absent in blast crisis (lane 6, Fig 3A) . These data suggest that there were two populations of cells present at the time of sampling of lane 7, Fig 3A, one that was normal and one that contained a p53 rearrangement. The p53 rearrangement was probably *Date at which sample was taken for cytogenetics is different from date at which sample was taken for Southern analysis in Table 3 . digest. (This is a hypothesis not formally proven by the data.) Alternatively, there are two populations of cells that are present in patient 7, one with both p53 alleles unrearranged a t the Southern level, and another population in which one p53 allele has been completely lost and the other p53 allele acquired in a clone of cells late in chronic phase, which was then superceded by other clones that lacked the rearrangement later in the evolution of the CML.
In the BglII digests of the chronic-phase DNA of patient 7 (Fig 3A, lane 2) , the 2.8-kb BglII fragment of the DNA of patient 7 was less intense than the 9.5-kb genomic fragment in lane 2. In a patient without any p53 rearrangement (Fig   3A, lane l) , the 2.8-kb BglII fragment is more intense than the 9.5-kb BglII fragment. This suggests that there has been a rearrangement in patient 7 in the region corresponding to the 2.8-kb BglII fragment in one of the alleles of p53 in patient 7, and that the 2.8-kb BglII fragment on the other allele of patient 7 is unrearranged, or that there are two populations of cells as outlined above. An abnormal EcoRI 5' fragment on one allele of p53 of patient 7 with 4.2 kb (Fig 3A, lane 5) was seen. Again the normal allele is less intense than the abnormal allele. These data further support the contention that two populations of cells may have been present in patient 7 at the time of sampling that led to the discovery of the rearranged p53 in chronic phase. On the basis of this data, we have concluded that rearrangements occurred at the 3' and. 5' ends in one allele of thep53 gene of patient 7. The extreme 5' limit of the rearrangement is undefined by this data. Figure 4A shows the Southern blot analysis of the DNA of patient 24. The HindIII digest of this patient (Fig 4A, lane 6) shows a complete disappearance of the 2.5-kb HindIII fragment, suggesting that both chromosomes have a p53 allele rearranged in the region of exons 2 through 5. As shown in lane 6, Fig 4A, the DNA of patient 24, when digested with HindIII, releases a 7.2-and a 7.0-kb p53 fragment. The DNA of a patient with an unrearranged p53 (Fig 4A, lane 7) generates a 7.0-kb and a 2.5-kb HindIII fragment. This suggests that on one allele of patient 24, the 7.0-kb HindIII fragment, is not rearranged, whereas on the other allele, a 7.2-kb Hind111 fragment is present that arose from the addition of 0.2 kb of DNA to the 3' 7.0-kb fragment. In other words, this is a rearranged fragment and contains sequences of the 2.5-kb band. Both alleles are rearranged a t the 5' end. The rearrangement has a 3' limit in the 5' end of exon 5 on the allele that contains the normal 7.0-kb HindIII fragment; whereas the 3' limit of the rearrangement on the allele that contains the 7.2-kb HindIII fragment extends beyond exon 5 in the 3' direction, but no further than the start of intron 10, because the BglII fragment is normal on both alleles (see below).
The 2.8-kb BgrII fragment in the DNA of patient 24 is more intense than the 9.5-kb BgZII genomic fragment of patient 24 ( Fig 4A, lane 1) as is the case in DNA in which p53 is not rearranged (lane 1, Fig 3A, or lane 3, Fig 4A) . Thus, a diploid complement of the 2.8-kb BgZII fragment is present in the DNA of patient 24 (lane 1, Fig 4A) . The 5' BglII fragment in one allele is 9.5 kb (normal) and is 3.0 kb in another (lane 1, Fig 4A) . The 3.0 kb could also be from the 3' end but this is less likely because the intensity of the 2.8-kb band is greater than the 11 .O-kb band in lane 1, Fig 4A. 1 and 21, EcoRl (lanes 3 through 5) . and Hindlll (lanes 6 and 7) . DNA from other patients in which the Southern analysis of p53 is normal at the Southern level is presented in lanes 1,3, and 4. DNA samples from patient 7 in chronic phase that show abnormal digests are in lanes 2, 5. and 7. In lanes 6 and 7. the DNA is from patient no. 7 in the blastic and chronic phase, respectively. The digest in lane 6 (blastic phase) shows a normal configuration to the Hindlll digest, whereas the sample from chronic phase (lane 7) shows an abnormal Hindlll fragment (3.7 kb). The same sat of samples from patient no. 7 in the blastic and chronic phase of CML is presented in lanes These data indicate that a rearrangement in p53 occurred on both alleles on the 5' end of the p53 gene. The extreme 5' limit of the rearrangement is not clarified by these digests. An abnormal 3.5-kb EcoRl fragment is also seen in lane 4, Fig 4A. A faint second band is seen just under the 15-kb EcoRl normal fragment in lane 4 of the EcoRl digest of patient 24 (Fig 4A) . This may be due to the presence of a subpopulation of cells in patient 24 because this minor band is much lighter than the 15-kb or the 3. Fig SA) , is not due to a sample was available for analysis from patient 24 before blastic transformation.
As shown by the HindIII, BgfIl, and EcoRl data presented for patients 7 and 24, the areas of p53 that were rearranged decreased amount of RNA added to lane 5. This shows that the expression of p53 was as great or greater in blast crisis than in chronic phase cells.
The data of Lubbert et a1: which was gathered on overlap in both of these patients in the exon 2 through 5 region. Such rearrangements were detectable at the Southern level in only 2 of 61 patients.
As shown in Table 3 and in Fig 4B (lanes 3 and 5) , two patients (no. 43 and 44) had abnormal fragments detectable with EcoRl but not with Bgfll or Hindlll digestion. The abnormal EcoRl fragments are 3.0 kb. These abnormal EcoR1 fragments could represent an EcoRl restriction endonuclease site polymorphism due to a point mutation that generates an additional EcoRl site without altering the sizes established cell lines. suggested that a reciprocal relationship existed between the levels of expression of the c-myc and p53 genes. We therefore compared the levels of expression of p53 and c-myc at the RNA level in chronic phase and blastic phase CML patients by hybridizing sequentially a Northern blot that contained both chronic phase and blast crisis samples with probes for c-myc and p53. In Fig 5C, the levels of p53 mRNA in CML patients no. 1 and 7 (lanes 1 and 2) who had progressed to myeloid blast crisis were equivalent to the c-myc mRNA in these patients. The c-myc levels were of other fragments. Point mutations have been detected by other workers in neoplastic tissue.2'
We also examined the levels of expression of both the c-myc oncogene and the p53 gene on Northern blots in 7 CML patients, two who were in chronic phase and five who were in blast crisis. The p53 mRNA was of normal size in all patients. As shown in Fig SA, and 64 who were in myeloid blast crisis (lanes 4 and 6). or slightly higher than the p53 signals in the chronic phase patients (lanes 3 through 5). As reported previously by others, the levels ofp53 mRNA do not always correlate with the levels of p53 thus our data do not rule out such a reciprocal relationship at the level of myc and p53 proteins.
These data show that thep53 mRNA is of normal size and that the level of p53 mRNA does not decrease as CML evolves into blast crisis. It is possible that the high level of p53 mRNA in blast crisis, as compared with chronic phase, reflected the fact that primitive hematopoietic cells that 
DISCUSSION
CML is a disease in which all of the leukemia cells in over 95% of the patients contain a rearrangement of the c-ubl oncogene, resulting in the creation of a fusion gene, the bcr-ubl gene. Although Andrews et al" have reported elevated levels of bcr-ubl mRNA during the transition from chronic phase to blast crisis, Shtivelman et alZo reported no consistent change of the levels of bcr-ubl mRNA during the evolution to blast crisis. Since many workers have proposed that thep53 is an "anti-oncogene,"*' we tested if the levels of p53 mRNA were lower in blast crisis than in chronic phase CML. Our data in five blastic-phase and two chronic-phase CML patients indicate that the levels of p53 mRNA in marrow cells of patients with the blast crisis stage of CML (three myeloid and two lymphoid) is as high or higher than the levels found in marrow cells of two chronic-phase CML patients. These data are consistent with previous reports which indicated that the p53 mRNA lever is higher in blast cells than in mature cell^.'^.'^ 
7
No change in the size of the p53 mRNA was seen in our five blast crisis patients with CML, or in a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL). Lubbert et aI9 reported a high level of p53 mRNA in 3 of 4 patients with CML. Similarly, Smith et al' reported expression of p.53 protein in leukemia cells in suspension isolated from acute myelogenous leukemia patients. However, the expression of p53 protein has been variable in many of these studies,"" and the level of p53 protein does not always correlate with the level of p53 mRNA.
We chose to look for changes in the p53 gene because of the high incidence of rearrangements of chromosome 17 in CML and in the short arm of chromosome 17 in nonHodgkin's ly~nphoma,~~.'~ as well as the reports of rearrangement of p53 on myeloid leukemia cell linez4 and in osteosarcomas.I9 In the 61 CML patients studied in our series, rearrangements were detectable at the Southern level in the 5' end of thep53 gene in both alleles of one patient and in one allele of another patient. In one of our patients, rearrangements at the 3' and 5' ends of one allele of the p53 gene were detectable. Major deletions in a majority of the exons of all alleles of the p53 gene have previously been reported in the HL60 cell line. 24 Deletions detectable by Southern analysis that were recently reported in osteogenic sarcoma cell lines were located within intron 1 of four patients, in the 3' exons of another, and in the 3' region of a fifth patient." Thus, only one of these patients with osteogenic sarcoma (the one with the exonic deletions) is similar to the rearrangements that we found in CML (exons 2 through 11). The cDNA p53 probe used in our studies did not cover exon 1. Therefore, it is possible that we would have detected a higher incidence of rearrangements in p53 if our probe had extended sufficiently 5' to include sequences of exon 1. Moreover, it is also possible that point mutations not detectable by Southern analysis are present in the p53 genes of CML patients, as has been reported in colon cancer.2i
A large number of rearrangements have been detected on the short arm of chromosome 17 in poor-prognosis nonHodgkin's lymphoma^.^^,^' Loss of heterozygosity has been noted in this region of chromosome 17 in carcinomas of the ~0 l 0 n .~~3~~ We did not detect loss of heterozygosity during the transition from chronic phase to blast crisis in seven of our patients who were informative for two polymorphic chromosome 17p probes in chronic phase. Our patients in whom structural rearrangements were detectable at the Southern level had no cytogenetically detectable rearrangements of chromosome 17. Baker et a]*' have reported that point mutations have been found in p53 in colon cancer where chromosome 17 abnormalities were detectable. It is clear that both p53 and chromosome 17 changes occur in a large variety of neoplastic tissue types.
Several parallels exist between our findings and those reported previously in the mouse system. Deletion of 5' coding sequences of p53 (exon 2 ) has been reported in the mouse, and it appears to stabilize the p53 pr~tein.~' p53 rearrangements that involve both alleles have been reported in mouse erythroleukemia systems," as we have found in humanp53 in our studies of CML. Wang et reported that p53 in its native state acts as an anti-oncogene that suppresses the function of intranuclear proliferation-stimulating proteins such as the large T-antigen of SV40. Once mutated, its ability to suppress the function of other oncogenes is diminished. Especially interesting in this regard are the reports that thep53 locus is a site for viral integration, which could disrupt the function of thep53
The rearrangement of both alleles in one of our CML patients (no. 24) and the suspicion that the other patient (no. 7) had a population of cells in which one allele was lost and the other allele rearranged is consistent with an anti-oncogene role of thep53 gene since it is felt that both alleles of an anti-oncogene must be lost before the cell is released from the regulatory influence of such a gene.
Much of the data about p53 is also consistent with it being able to develop into an "oncogene." Perhaps the site of point mutational change in the p53 gene may determine whether loss of the anti-oncogene function occurs or transition to an oncogene function may arise. The structure of the human p53 gene3' is similar in organization to that of the mouse. Interesting in this regard is the report of a mutant p53 gene, the presence of which results in cells that are insensitive to transformation by activated ras oncogenes. 33 It is interesting that two groups have found the incidence of ras activation in CML to be very low.34,35 It is also possible that the primary site where loss of genetic material is occurring in disorders in which chromosome 17 loss or rearrangement occurs may involve a gene distinct from p53 but which is in the vicinity of p53. Our data suggest that further study with anonymous polymorphic probes of hematopoietic neoplasms associated with rearrangements of the short arm of chromosome 17 and sequence amplification assays designed to detect point mutations of p53 is warranted to determine if a reproducible loss or alteration of genetic material from this region of chromosome 17 is associated with the evolution of leukemia.
